Newron Pharmaceuticals (NWPHF) Stock Price, News & Analysis

Company Overview

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.

Key Stats

• Today's Range: $9.36 to $9.36
• 50-Day Range: $9.10 to $9.36
• 52-Week Range: $9.10 to $12.00
• Volume: N/A
• Average Volume: 600 shs
• Market Capitalization: $167.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NWPHF Stock Analysis - Frequently Asked Questions

How have NWPHF shares performed this year?

Newron Pharmaceuticals' stock was trading at $5.22 on January 1st, 2024. Since then, NWPHF stock has increased by 79.3% and is now trading at $9.36.
View the best growth stocks for 2024 here.

How do I buy shares of Newron Pharmaceuticals?

Shares of NWPHF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Today: 11/05/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:NWPHF
• CUSIP: N/A
• CIK: N/A
• Web: www.newron.com
• Phone: (902) 610-3461
• Fax: 39-02-6103-4654
• Employees: 22
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $6.82 million
• Price / Sales: 24.50
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.21 per share
• Price / Book: 44.57

Miscellaneous

• Outstanding Shares: 17,850,000
• Free Float: N/A
• Market Cap: $167.08 million
• Optionable: Not Optionable
• Beta: 0.53